Navigation Links
New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
Date:9/19/2007

statement as a result of new information, future events or other factors. Forward- looking statements are inherently uncertain, and investors must recognize that events could differ significantly from our expectations. In addition to the risks and uncertainties noted in this release, there are certain factors that could cause actual results to differ materially from those anticipated by some of the statements made. These include: (1) the ability to achieve business plans, including with respect to lower income consumers and growing existing sales and volume profitably despite high levels of competitive activity, especially with respect to the product categories and geographical markets (including developing markets) in which the Company has chosen to focus; (2) the ability to successfully execute, manage and integrate key acquisitions and mergers, including (i) the Domination and Profit Transfer Agreement with Wella, and (ii) the Company's merger with The Gillette Company, and to achieve the cost and growth synergies in accordance with the stated goals of these transactions; (3) the ability to manage and maintain key customer relationships; (4) the ability to maintain key manufacturing and supply sources (including sole supplier and plant manufacturing sources); (5) the ability to successfully manage regulatory, tax and legal matters (including product liability, patent, and intellectual property matters as well as those related to the integration of Gillette and its subsidiaries), and to resolve pending matters within current estimates; (6) the ability to successfully implement, achieve and sustain cost improvement plans in manufacturing and overhead areas, including the Company's outsourcing projects; (7) the ability to successfully manage currency (including currency issues in volatile countries), debt, interest rate and commodity cost exposures; (8) the ability to manage continued global political and/or economic uncertainty and disruptions, especially in the Co
'/>"/>
SOURCE The Alliance for Better Bone Health
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... May 28, 2015  Eli Lilly and Company (NYSE: ... announced cash tender offer for up to $1.6 billion aggregate ... Holders of notes who tendered, and did not validly ... New York City time, on May 27, 2015 ... by Lilly, are eligible to receive the total consideration. The ...
(Date:5/28/2015)... 28, 2015  Maetrics ( http://maetrics.com ), a leading ... wrapped up a successful conference, "The cost of non-compliance -- ... today in Zurich . ... its Switzerland -based team, experts provided ... Technology field to an exclusive local audience. The event ...
(Date:5/28/2015)... -- This report analyzes the worldwide markets for Intraocular Lenses ... Standard Intraocular Lenses, and Premium Intraocular Lenses. The report provides ... , Japan , Europe ... , and Rest of World. Annual estimates and forecasts ... seven-year historic analysis is provided for these markets. Market data ...
Breaking Medicine Technology:Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Maetrics Hosts Innovative Medical Cluster Event in Switzerland 2World Intraocular Lenses Industry 2World Intraocular Lenses Industry 3World Intraocular Lenses Industry 4World Intraocular Lenses Industry 5World Intraocular Lenses Industry 6World Intraocular Lenses Industry 7World Intraocular Lenses Industry 8World Intraocular Lenses Industry 9World Intraocular Lenses Industry 10World Intraocular Lenses Industry 11World Intraocular Lenses Industry 12World Intraocular Lenses Industry 13World Intraocular Lenses Industry 14World Intraocular Lenses Industry 15World Intraocular Lenses Industry 16World Intraocular Lenses Industry 17World Intraocular Lenses Industry 18World Intraocular Lenses Industry 19World Intraocular Lenses Industry 20World Intraocular Lenses Industry 21World Intraocular Lenses Industry 22World Intraocular Lenses Industry 23World Intraocular Lenses Industry 24World Intraocular Lenses Industry 25World Intraocular Lenses Industry 26
... Lexicon Pharmaceuticals, Inc. (Nasdaq: ... treatments for human disease, announced data from a recently ... oral dose formulation for LX4211, a dual inhibitor of ... Results from the study demonstrated that administration of ...
... Jan. 5, 2011 The pharmaceutical industry,s steep ... strategy and development executives to uncover opportunities for ... combination therapies with branded products to extend patent ... products can extend a therapeutic advantage and become ...
Cached Medicine Technology:Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients 2Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients 3Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients 4Report Highlights Successful Strategies for Bringing FDC Products to Market 2
(Date:5/29/2015)... Mediaplanet has joined forces with Raw Elements ... importance of proper sun protection. The print component of ... circulation of approximately 250,000 copies and an estimated readership ... through a vast social media strategy, and across a ... explore the digital version of the campaign, click ...
(Date:5/29/2015)... Ca (PRWEB) May 29, 2015 ... pain consultations with specialists, physical therapy, and injections ... experiencing mid back and/or lower back pain, Healthpointe ... epidural injections for herniated discs, disc protrusions and ... . , Healthpointe’s team of renowned surgeons ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 The ... giving patients a long-lasting impression on what modern dentistry ... VisitandCare.com is on a mission to revolutionize the perception ... with a high-class Wellness & Spa. , The ... world’s most successful medical tourism agencies and ...
(Date:5/29/2015)... MN (PRWEB) May 29, 2015 As ... Patio and Metro series outdoor saunas have increased in ... landscaping projects, and work at summer cottages. While ... piqued interest in summer projects a few weeks earlier ... suburban communities with smaller lot sizes tend to prefer ...
(Date:5/29/2015)... 29, 2015 Vulvodynia is defined as ... significant physical, sexual, and psychological distress. Women’s ... Vulvodynia. The actual diagnosis is often made on the ... realize that this problem can be very troublesome to ... these symptoms, they need to schedule and appointment with ...
Breaking Medicine News(10 mins):Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 2Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 3Health News:As Summer Approaches, Finnleo Notes Increased Interest in Patio and Metro Outdoor Saunas 2
... Liberator Medical,Holdings, Inc. (OTC Bulletin Board: LBMH.OB) reported ... 2007 sales, which is thus far,the highest sales ... the Company,s ongoing continuous targeted advertising effort., ... our November,sales, we believe that in our first ...
... near crowded roadways face more than 50% risk of breathing ... Children with asthma who are exposed to traffic pollution are ... says a study that looked at children in the Mexican ... United States. , "Major cities along the northern and ...
... 13 The Ensign,Group, Inc. (Nasdaq: ENSG ... of,skilled nursing, rehabilitative care services and assisted living,companies, ... two skilled,nursing facilities in California and one assisted ... of approximately $12.8 million., (Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ...
... part of its ongoing,global campaign to lower drug prices ... worldwide, AIDS Healthcare Foundation,(AHF) today responded to a modest ... Cipla, on three of its antiretroviral drugs to,fight HIV/AIDS. ... AHF-led,advocacy campaign aimed at pressuring Cipla to lower its ...
... in patients battling stomach cancer , , THURSDAY, Dec. 13 ... sunitinib (Sutent), which fights stomach tumors, can also create ... , All patients taking sunitinib, but especially those ... and treatment for high blood pressure and other signs ...
... Pro Bowler and TODAY,correspondent Tiki Barber spoke publicly for ... affects such a wide range of people in,different circumstances ... he told Meredith Vieira this morning on TODAY., ... founding,member and president, also appeared on TODAY to discuss ...
Cached Medicine News:Health News:Liberator Medical Supply Exceeds Projected November Sales 2Health News: Traffic Pollution Hurts Asthmatic Kids' Lungs 2Health News:The Ensign Group, Inc. Acquires Assets of Three Previously Leased Facilities 2Health News:Cipla Offers Modest AIDS Drug Price Cut: 'Not Nearly Enough,' says AHF 2Health News:Cipla Offers Modest AIDS Drug Price Cut: 'Not Nearly Enough,' says AHF 3Health News:New Cancer Drug Tied to Heart Problems 2Health News:New Cancer Drug Tied to Heart Problems 3Health News:New Cancer Drug Tied to Heart Problems 4Health News:Former NFL Star Tiki Barber and CURE Founder Susan Axelrod Speak Out About Epilepsy on TODAY Show 2
2.0mm Rounded Tip, 12mm From Tip to Bend Gently Curved, 15mm Shaft; In Titanium...
Double ended with 0.5mm x 10mm and 1.0mm x 15mm blades; both blades gently curved; round serrated handle, In Titanium....
0.6mm Tip x10mm Shaft, Straight Shaft, 90 Degree Hook at Tip; overall length 120mm; in Titianium....
... The SURPASS Perfusion Catheter is ... the stenotic portion of a ... stenosis for the purpose of ... Perfusion Catheters are also designed ...
Medicine Products: